长寿科学正在成为主流。以下是《彭博商业周刊》长寿特刊刚刚发表的一篇新文章：
纽约市哥伦比亚大学欧文医学中心研究卵巢衰老的研究员Yousin Suh表示：“直到最近，这个领域还没有资金支持，也没有引起人们的兴趣。”医学领域长期存在的性别偏见导致女性生殖系统的研究严重不足。
科学家和初创公司正在竞相将这些发现转化为疗法，有一天可能会推进更年期和不孕症的治疗，并可能最终干预衰老本身的过程。威廉姆斯和苏已经开始招募女性参加一项临床试验，以测试雷帕霉素（一种通常用于器官移植和癌症治疗的免疫抑制剂，也已成为一种流行的抗衰老药物）是否也能延缓卵巢衰老。西北大学的研究人员正在探索抗纤维化药物是否可以提高女性随着年龄增长的卵子质量以及延长生殖寿命。一家名为Gameto的初创公司利用干细胞科学创建了强度较低的 IVF，并计划使用相同的技术来创建更好的更年期疗法。
两年半前，佩平与多纳霍和哈佛大学博士一起。 Daisy Robinton 在专注于衰老的药物开发公司Cambrian BioPharma Inc.的资助下创立了Oviva Therapeutics Inc.。他们的目标是：将 AMH 转化为可以改善卵巢功能和延长寿命的治疗方法。佩平说，在衰老研究领域，卵巢可能是唾手可得的成果。与整个身体相比，干预一个器官的衰老是一项小得多的任务。 “如果你想延长寿命，那就很难了，”佩平说。 “但是卵巢真的很奇怪。它比其他任何东西都更早开始退化。因此，即使你不碰其他任何东西，你也可以很容易地看到对卵巢的影响。”
根据市场研究公司 Imarc Group 的数据，全球生育市场去年价值约 35.2 亿美元，预计到 2028 年将增长至 840 亿美元。 Oviva 于 2022 年 5 月筹集了1150 万美元用于早期治疗，旨在通过帮助患者增加每个周期的卵子数量来改善生育治疗。最终，Oviva 希望完成一项几乎难以想象的壮举：为女性提供一种药物，让她们能够选择何时以及是否经历更年期。当政客们正在侵蚀女性来之不易的生育选择权时，Oviva 的创始人希望给予她们更多的控制权。 “我认为这非常类似于避孕药如何真正改变了 70 年代女性的游戏规则，”罗宾顿说。
…
在哥伦比亚大学，Suh 和 Williams 正在招募约 50 名女性进行一项试点研究，以了解已有数十年历史的器官移植药物雷帕霉素如何影响卵巢衰老。雷帕霉素作用于人体的mTOR 通路，这是长寿界的流行词：mTOR 通路的激活似乎与衰老有关，表明对其进行干预可以减缓这一过程。但它似乎也在原始卵泡的激活中发挥着作用，这就提出了一个问题：针对 mTOR 通路是否可以降低这些卵泡的成熟速度。西北大学生育力保存医学主任兼副教授Kara Goldman探索了 mTOR 抑制药物如何保护小鼠免受癌症治疗导致的卵子快速消耗。现在苏和威廉姆斯正在将这项工作应用于人类。 “我们非常有信心雷帕霉素可以帮助女性延缓卵巢衰老，从而改善身体衰老，”Suh 说。
全文：https: //archive.ph/2a4sl
相关阅读：
这里： 女性服用雷帕霉素来增强生育能力/预防更年期？
此处： 2023 年长寿峰会亮点
这里：彭博商业周刊：长寿问题
7 Likes
Other stories in this Longevity Issue:
We Are So Not Ready for a Society Where Living to 100 Is Common
A few takeaways from working at the Stanford Center on Longevity.
One Man’s Longevity Obsession Now Includes Fountain-of-Youth Injections
A startup called Minicircle wants to reprogram human genes—and is enlisting biohacker Bryan Johnson as a human guinea pig in its unproven approach.
Anti-Aging Cosmetics
Dermatologists say consumers should be wary of scientific-sounding skin-care routines on TikTok and Instagram. So what should you do instead?
2 Likes
More from this issue:
What Dermatologists Really Think About Those Anti-Aging Products
Cosmetics companies are trying to wow consumers with clinical-sounding ingredients. Actual scientists aren’t impressed.
Beauty companies big and small are increasingly using science—or at least words and phrases that sound like they’re pulled from a peer-reviewed journal—to market their products. The dollar value of products sold in the US that say they include clinical ingredients, such as niacinamide and hyaluronic acid (both can help hydrate skin), has been growing at an average annual rate of 71.5% during the past five years versus 5.3% for overall skin-care items, says Jacqueline Flam Stokes, senior vice president for beauty, drug and over-the-counter retail at NielsenIQ, a data firm. The surge in demand for ingredient-led products has surpassed consumer interest in beauty items marketed as “natural” or “organic,” which were particularly popular before the pandemic, she says.
Take ceramides, lipid molecules that can help preserve moisture and protect against skin irritation. “Ceramides have been a very popular ingredient in cosmetics and skin-care products for decades,” Flam Stokes says. “What we’ve seen over the last three years, really, is that ceramides are now a popular ingredient that’s being called out on the front of packing labels.”
Welcome to the scientification of skin care. The trend gathered momentum during the pandemic, when Americans were spending countless hours eyeing themselves on video chats. That prodded many to try to address their perceived skin imperfections. With guidance from skin-care influencers on TikTok and elsewhere, shoppers snapped up clinical-sounding beauty products to expand their facial routines to half a dozen steps or more.
Full article: https://archive.ph/FPNeS
An article mostly about the ITP program / Richard Miller (and Yuvan / E5 later in the story)
What the Oldest Lab Rodents Are Teaching Humans About Staying Young
Some of the longest-living rats and mice—including the very adorable dwarf mouse—could help unlock the mysteries of aging.
Over the years, the ITP has surfaced several promising life-span-increasing interventions. The most successful, mousewise, is a combination of the immunosuppressive drug rapamycin and the glucose regulator acarbose, which allowed mice in the ITP to live an average of 29% longer. Other stakeholders are now investigating these and other successful drugs further, in mice, different study animals or occasionally themselves, Miller says.
全文：https://archive.ph/ZMsX0
